1. Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004; 75:1135–1140. PMID:
15258215.
Article
2. Lancaster E. Paraneoplastic disorders. Continuum (Minneap Minn). 2015; 21(2 Neuro-oncology):452–475. PMID:
25837906.
Article
3. Tada S, Furuta M, Fukada K, Hirozawa D, Matsui M, Aoike F, et al. Severe parkinsonism associated with anti-CRMP5 antibody-positive paraneoplastic neurological syndrome and abnormal signal intensity in the bilateral basal ganglia. J Neurol Neurosurg Psychiatry. 2016; 87:907–910. PMID:
26374701.
Article
4. Kannoth S, Anandakkuttan A, Mathai A, Sasikumar AN, Nambiar V. Autoimmune atypical parkinsonism-a group of treatable parkinsonism. J Neurol Sci. 2016; 362:40–46. PMID:
26944115.
5. Golbe LI, Miller DC, Duvoisin RC. Paraneoplastic degeneration of the substantia nigra with dystonia and parkinsonism. Mov Disord. 1989; 4:147–152. PMID:
2543919.
Article
6. Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol. 2003; 53:580–587. PMID:
12730991.
Article